Your session is about to expire
← Back to Search
Modakafusp Alfa for Multiple Myeloma (iinnovate-1 Trial)
iinnovate-1 Trial Summary
This trial will test the safety and efficacy of modakafusp alfa in people with relapsed or refractory multiple myeloma.
iinnovate-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowiinnovate-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 122 Patients • NCT01474915iinnovate-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had a stem cell transplant and no ongoing immune system treatment for graft disease.I have a specific blood or bone marrow condition like POEMS syndrome or Waldenstrom macroglobulinemia.I have recovered from previous myeloma treatments, except for some remaining nerve issues.My multiple myeloma is progressing and I need more treatment.I have had at least 3 different treatments for myeloma.I have measurable myeloma or symptoms, and I can care for myself.My multiple myeloma has affected my brain or spinal cord.I have hepatitis B or C but haven't tested positive for active HBV DNA.I don't have certain blood disorders or another cancer besides MM in the last 3 years.I have multiple myeloma needing more treatment due to worsening.I have not responded to or cannot tolerate at least one proteasome inhibitor and one immunomodulatory drug.My condition worsened despite treatments with specific cancer drugs.I have undergone at least 3 different treatments for myeloma.
- Group 1: Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD
- Group 2: Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD
- Group 3: Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg
- Group 4: Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg
- Group 5: Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD
- Group 6: Part 3 (Dose Extension): Modakafusp alfa 120 mg
- Group 7: Part 3 (Dose Extension): Modakafusp alfa 240 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other investigations have been conducted for the evaluation of TAK-573?
"Presently, there are 553 active clinical trials testing the effects of TAK-573 with 144 in their final phase. These studies span 18625 different locations, however a majority are held within Mishawaka, Indiana."
Are there any remaining slots available for this experiment?
"The clinical trial, first published on October 4th 2017 is currently enrolling participants according to information hosted by clinicialtrials.gov. The listing was last amended on November 10th 2022."
In how many facilities is this experiment being conducted?
"This medical trial is enrolling patients at multiple locations including Baptist Cancer Center - Memphis - Walnut Grove in Memphis, Tennessee; Swedish Medical Center in Seattle, Washington; and Duke University Medical Center in Durham, North carolina amongst 36 other sites."
For how many participants is this clinical trial recruiting?
"Researchers need to recruit 336 eligible patients for the trial, who can partake from various sites such as Baptist Cancer Center - Memphis - Walnut Grove in Tennessee and Swedish Medical Center in Washington."
In what ways is TAK-573 typically employed by clinicians?
"Physicians often turn to TAK-573 for treating ophthalmia, sympathetic. Additionally, this pharmaceutical agent can be applied in the management of eye branch retinal vein occlusion and macular edema."
Share this study with friends
Copy Link
Messenger